# INTerpath-13 (NCT07221474)

> A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07221474
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Squamous Non-small Cell Lung Cancer
- Interventions: Intismeran Autogene; Pembrolizumab; Carboplatin; Paclitaxel; Nab-paclitaxel; Placebo
- Enrollment: 180
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on INTerpath-13 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=interpath-13-nct07221474